vs
查尔斯河实验室（CRL）与莫德纳（MRNA）财务数据对比。点击上方公司名可切换其他公司
莫德纳的季度营收约是查尔斯河实验室的1.0倍（$1.0B vs $994.2M），莫德纳净利率更高（-19.7% vs -27.8%，领先8.1%），查尔斯河实验室同比增速更快（-0.8% vs -45.4%），查尔斯河实验室自由现金流更多（$58.6M vs $-880.0M），过去两年查尔斯河实验室的营收复合增速更高（-0.9% vs -45.0%）
查尔斯河实验室国际是总部位于美国马萨诸塞州威尔明顿的医药及生物技术领域合同研究组织（CRO），成立于1947年，可为新药、疫苗及医疗器械的研发提供临床前和临床阶段的专业实验室服务。
莫德纳是一家总部位于美国马萨诸塞州剑桥市的生物制药企业，深耕RNA治疗领域，核心业务聚焦mRNA疫苗研发。其疫苗通过信使RNA（mRNA）分子拷贝传递蛋白合成指令以触发人体免疫反应，公司名称由“修饰”“RNA”与“现代”三个词组合而来。
CRL vs MRNA — 直观对比
营收规模更大
MRNA
是对方的1.0倍
$994.2M
营收增速更快
CRL
高出44.6%
-45.4%
净利率更高
MRNA
高出8.1%
-27.8%
自由现金流更多
CRL
多$938.6M
$-880.0M
两年增速更快
CRL
近两年复合增速
-45.0%
损益表 — Q4 FY2025 vs Q3 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $994.2M | $1.0B |
| 净利润 | $-276.6M | $-200.0M |
| 毛利率 | — | 79.6% |
| 营业利润率 | -28.5% | -25.6% |
| 净利率 | -27.8% | -19.7% |
| 营收同比 | -0.8% | -45.4% |
| 净利润同比 | -28.9% | -1638.5% |
| 每股收益（稀释后） | $-5.57 | $-0.51 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CRLMRNA
| Q4 25 | $994.2M | — | ||
| Q3 25 | $1.0B | $1.0B | ||
| Q2 25 | $1.0B | — | ||
| Q1 25 | $984.2M | — | ||
| Q4 24 | $1.0B | $966.0M | ||
| Q3 24 | $1.0B | $1.9B | ||
| Q2 24 | $1.0B | — | ||
| Q1 24 | $1.0B | — |
净利润CRLMRNA
| Q4 25 | $-276.6M | — | ||
| Q3 25 | $54.4M | $-200.0M | ||
| Q2 25 | $52.3M | — | ||
| Q1 25 | $25.5M | — | ||
| Q4 24 | $-214.5M | $-1.1B | ||
| Q3 24 | $69.7M | $13.0M | ||
| Q2 24 | $94.1M | — | ||
| Q1 24 | $73.0M | — |
毛利率CRLMRNA
| Q4 25 | — | — | ||
| Q3 25 | — | 79.6% | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 23.5% | ||
| Q3 24 | 34.6% | 72.4% | ||
| Q2 24 | 34.5% | — | ||
| Q1 24 | 34.1% | — |
营业利润率CRLMRNA
| Q4 25 | -28.5% | — | ||
| Q3 25 | 13.3% | -25.6% | ||
| Q2 25 | 9.7% | — | ||
| Q1 25 | 7.6% | — | ||
| Q4 24 | -16.7% | -129.0% | ||
| Q3 24 | 11.6% | -3.8% | ||
| Q2 24 | 14.8% | — | ||
| Q1 24 | 12.5% | — |
净利率CRLMRNA
| Q4 25 | -27.8% | — | ||
| Q3 25 | 5.4% | -19.7% | ||
| Q2 25 | 5.1% | — | ||
| Q1 25 | 2.6% | — | ||
| Q4 24 | -21.4% | -115.9% | ||
| Q3 24 | 6.9% | 0.7% | ||
| Q2 24 | 9.2% | — | ||
| Q1 24 | 7.2% | — |
每股收益（稀释后）CRLMRNA
| Q4 25 | $-5.57 | — | ||
| Q3 25 | $1.10 | $-0.51 | ||
| Q2 25 | $1.06 | — | ||
| Q1 25 | $0.50 | — | ||
| Q4 24 | $-4.17 | $-2.91 | ||
| Q3 24 | $1.33 | $0.03 | ||
| Q2 24 | $1.74 | — | ||
| Q1 24 | $1.30 | — |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $213.8M | $1.1B |
| 总债务越低越好 | $2.1B | — |
| 股东权益账面价值 | $3.2B | $9.3B |
| 总资产 | $7.1B | $12.1B |
| 负债/权益比越低杠杆越低 | 0.68× | — |
8季度趋势，按日历期对齐
现金及短期投资CRLMRNA
| Q4 25 | $213.8M | — | ||
| Q3 25 | $207.1M | $1.1B | ||
| Q2 25 | $182.8M | — | ||
| Q1 25 | $229.4M | — | ||
| Q4 24 | $194.6M | $1.9B | ||
| Q3 24 | $210.2M | $1.6B | ||
| Q2 24 | $179.2M | — | ||
| Q1 24 | $327.0M | — |
总债务CRLMRNA
| Q4 25 | $2.1B | — | ||
| Q3 25 | $2.2B | — | ||
| Q2 25 | $2.3B | — | ||
| Q1 25 | $2.5B | — | ||
| Q4 24 | $2.2B | — | ||
| Q3 24 | $2.3B | — | ||
| Q2 24 | $2.4B | — | ||
| Q1 24 | $2.7B | — |
股东权益CRLMRNA
| Q4 25 | $3.2B | — | ||
| Q3 25 | $3.4B | $9.3B | ||
| Q2 25 | $3.4B | — | ||
| Q1 25 | $3.2B | — | ||
| Q4 24 | $3.5B | $10.9B | ||
| Q3 24 | $3.8B | $11.9B | ||
| Q2 24 | $3.7B | — | ||
| Q1 24 | $3.6B | — |
总资产CRLMRNA
| Q4 25 | $7.1B | — | ||
| Q3 25 | $7.5B | $12.1B | ||
| Q2 25 | $7.6B | — | ||
| Q1 25 | $7.6B | — | ||
| Q4 24 | $7.5B | $14.1B | ||
| Q3 24 | $8.0B | $15.8B | ||
| Q2 24 | $7.9B | — | ||
| Q1 24 | $8.2B | — |
负债/权益比CRLMRNA
| Q4 25 | 0.68× | — | ||
| Q3 25 | 0.64× | — | ||
| Q2 25 | 0.70× | — | ||
| Q1 25 | 0.79× | — | ||
| Q4 24 | 0.65× | — | ||
| Q3 24 | 0.62× | — | ||
| Q2 24 | 0.65× | — | ||
| Q1 24 | 0.73× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $147.5M | $-847.0M |
| 自由现金流经营现金流 - 资本支出 | $58.6M | $-880.0M |
| 自由现金流率自由现金流/营收 | 5.9% | -86.6% |
| 资本支出强度资本支出/营收 | 8.9% | 3.2% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $518.5M | $-1.9B |
8季度趋势，按日历期对齐
经营现金流CRLMRNA
| Q4 25 | $147.5M | — | ||
| Q3 25 | $213.8M | $-847.0M | ||
| Q2 25 | $204.6M | — | ||
| Q1 25 | $171.7M | — | ||
| Q4 24 | $159.4M | $825.0M | ||
| Q3 24 | $251.8M | $-1.6B | ||
| Q2 24 | $193.5M | — | ||
| Q1 24 | $129.9M | — |
自由现金流CRLMRNA
| Q4 25 | $58.6M | — | ||
| Q3 25 | $178.2M | $-880.0M | ||
| Q2 25 | $169.3M | — | ||
| Q1 25 | $112.4M | — | ||
| Q4 24 | $83.7M | $303.0M | ||
| Q3 24 | $213.1M | $-1.7B | ||
| Q2 24 | $154.0M | — | ||
| Q1 24 | $50.7M | — |
自由现金流率CRLMRNA
| Q4 25 | 5.9% | — | ||
| Q3 25 | 17.7% | -86.6% | ||
| Q2 25 | 16.4% | — | ||
| Q1 25 | 11.4% | — | ||
| Q4 24 | 8.4% | 31.4% | ||
| Q3 24 | 21.1% | -92.2% | ||
| Q2 24 | 15.0% | — | ||
| Q1 24 | 5.0% | — |
资本支出强度CRLMRNA
| Q4 25 | 8.9% | — | ||
| Q3 25 | 3.5% | 3.2% | ||
| Q2 25 | 3.4% | — | ||
| Q1 25 | 6.0% | — | ||
| Q4 24 | 7.5% | 54.0% | ||
| Q3 24 | 3.8% | 8.1% | ||
| Q2 24 | 3.8% | — | ||
| Q1 24 | 7.8% | — |
现金转化率CRLMRNA
| Q4 25 | — | — | ||
| Q3 25 | 3.93× | — | ||
| Q2 25 | 3.91× | — | ||
| Q1 25 | 6.74× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 3.61× | -120.46× | ||
| Q2 24 | 2.06× | — | ||
| Q1 24 | 1.78× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CRL
| Discovery And Safety Assessment Segment | $591.6M | 60% |
| Manufacturing Support Segment | $196.4M | 20% |
| Transferred At Point In Time | $108.0M | 11% |
| Transferred Over Time | $98.3M | 10% |
MRNA
| COVID19 | $971.0M | 96% |
| Other Revenue | $20.0M | 2% |
| Grant | $14.0M | 1% |
| Collaboration Arrangement Including Arrangements With Affiliate | $7.0M | 1% |
| License And Royalty | $2.0M | 0% |
